Advising large Japanese pharma company on its bid for a licence for a cancer drug from a UK biotechnology company involving a review of the patent situation in 19 jurisdictions.
Advising a public sector organization on the establishment of a US$800m SAP-based business transformation framework agreement.
Advising a manufacturer of construction equipment on IP licenses and technical services agreements in joint ventures with Chinese and Japanese entities.
Advising Genzyme on its strategic agreement with Bayer regarding Genzyme's hematologic oncology portfolio, including worldwide rights for Alemtuzumab (earn-out arrangement).
